Steven Narod

Summary

Affiliation: Women's College Hospital
Country: Canada

Publications

  1. Narod S. Breast cancer in young women. Nat Rev Clin Oncol. 2012;9:460-70 pubmed publisher
    ..It is hoped that by increasing breast cancer awareness, the proportion of invasive breast cancers that are diagnosed at 2.0 cm or smaller will increase and that this will lead to a reduction in mortality. ..
  2. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino W, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;: pubmed publisher
    ..However, uptake of both BSO and breast MRI is not optimal, and interventions to increase uptake are needed. ..
  3. Narod S. Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'". Hum Genet. 2019;: pubmed publisher
    ..In the event that a cancer screening program is an effective means of mortality reduction, then the best strategy is universality. The benefit of a novel intervention should be evaluated prior to its introduction. ..
  4. Kotsopoulos J, Lubinski J, Lynch H, Tung N, Armel S, Senter L, et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;: pubmed publisher
    ..Overall, our findings suggest that oophorectomy has little impact on the risk of contralateral breast cancer. ..
  5. Metcalfe K, Lynch H, Foulkes W, Tung N, Olopade O, Eisen A, et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019;120:398-403 pubmed publisher
    ..03). The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer. ..
  6. Lubinski J, Huzarski T, Gronwald J, Cybulski C, Debniak T, Sun P, et al. Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. Breast Cancer Res Treat. 2019;174:769-774 pubmed publisher
  7. Sopik V, Sun P, Narod S. Predictors of time to death after distant recurrence in breast cancer patients. Breast Cancer Res Treat. 2019;173:465-474 pubmed publisher
    ..This suggests that for ER-positive patients, the factors that determine the time from diagnosis to distant recurrence do not predict the course of the cancer post-recurrence. ..
  8. Narod S, Giannakeas V, Sopik V. Time to death in breast cancer patients as an indicator of treatment response. Breast Cancer Res Treat. 2018;172:659-669 pubmed publisher
    ..The use of time-to-death statistics to display mortality benefits for treated versus untreated women helps facilitate the distinction between treatments which increase the likelihood of cure and treatments that delay cancer growth. ..
  9. Narod S. Personalised medicine and population health: breast and ovarian cancer. Hum Genet. 2018;137:769-778 pubmed publisher
    ..The review focuses on strategies to reduce mortality from breast and ovarian cancer but is potentially applicable to other cancer sites, such as colon, prostate, and endometrial. ..

More Information

Publications50

  1. Kelemen L, Earp M, Fridley B, Chenevix Trench G, Fasching P, Beckmann M, et al. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. Int J Mol Sci. 2018;19: pubmed publisher
    ..51, p = 1.7 × 10-28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small. ..
  2. Kotsopoulos J, Prescott J, De Vivo I, Fan I, McLaughlin J, Rosen B, et al. Telomere length and mortality following a diagnosis of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:2603-6 pubmed publisher
    ..Our data provide preliminary evidence that telomere length likely does not predict outcome after a diagnosis of ovarian cancer. This represents the first study to suggest no prognostic role of telomere length for ovarian cancer. ..
  3. Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150:85-91 pubmed publisher
  4. Vicus D, Rosen B, Lubinski J, Domchek S, Kauff N, Lynch H, et al. Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol. 2009;115:135-137 pubmed publisher
    ..54-1.49, p=0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p=0.36). Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers. ..
  5. Kotsopoulos J, Gronwald J, Lynch H, Eisen A, Neuhausen S, Tung N, et al. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018;171:421-426 pubmed publisher
    ..This matched analysis of a large number of BRCA mutation carriers suggests that age at first birth has little influence on BRCA1 or BRCA2 breast cancer risk. ..
  6. Sopik V, Narod S. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170:647-656 pubmed publisher
    ..This calls into question the conventional model that the capacity for a primary breast tumour to metastasize increases as the tumour enlarges. ..
  7. Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin J, Risch H, et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol. 2016;140:42-7 pubmed publisher
    ..The strongest predictor of long-term survival is status of no residual disease at resection. ..
  8. Narod S, Dent R, Foulkes W. CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark. Clin Cancer Res. 2015;21:3813-4 pubmed publisher
    ..Finding successful treatment strategies for women with triple-negative breast cancer remains a challenge. ..
  9. Sopik V, Iqbal J, Rosen B, Narod S. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol. 2015;138:741-9 pubmed publisher
    ..Based on recent changes in risk factor propensity, we predict that the trend of the declining age-adjusted incidence rate of ovarian cancer in the United States will reverse and rates will increase in coming years. ..
  10. Sopik V, Rosen B, Giannakeas V, Narod S. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol. 2015;138:757-61 pubmed publisher
  11. Giannakeas V, Sopik V, Shestopaloff K, Iqbal J, Rosen B, Akbari M, et al. A model for estimating ovarian cancer risk: application for preventive oophorectomy. Gynecol Oncol. 2015;139:242-7 pubmed publisher
    ..Approximately 12.9% of all ovarian cancers in Ontario occur in the 0.7% of women in the general population who have a lifetime ovarian cancer risk in excess of 5%, the majority of whom carry a mutation in BRCA1 or BRCA2. ..
  12. Sopik V, Iqbal J, Rosen B, Narod S. Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecol Oncol. 2015;138:750-6 pubmed publisher
    ..The impact of these treatment modalities on ovarian cancer mortality still needs to be evaluated. ..
  13. Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16:638-44 pubmed publisher
    ..Increased surveillance should be offered to unaffected women who carry a PALB2 mutation. Polish National Science Centre. ..
  14. Arcand S, Akbari M, Mes Masson A, Provencher D, Foulkes W, Narod S, et al. Germline TP53 mutational spectrum in French Canadians with breast cancer. BMC Med Genet. 2015;16:24 pubmed publisher
    ..Although all newly identified breast cancer mutation carriers reported a family history of cancer, none were consistent with features of Li-Fraumeni syndrome families. ..
  15. Liede A, Jerzak K, Hernandez R, Wade S, Sun P, Narod S. The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat. 2016;156:587-595 pubmed publisher
  16. Giannakeas V, Sopik V, Narod S. A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. Breast Cancer Res Treat. 2018;169:587-594 pubmed publisher
    ..This lends support to the hypothesis that DCIS mortality is not restricted to those women who experience an in-breast invasive cancer and that DCIS has properties similar to small invasive breast cancers. ..
  17. Narod S, Sopik V. Is invasion a necessary step for metastases in breast cancer?. Breast Cancer Res Treat. 2018;169:9-23 pubmed publisher
    ..Cancer cells which disseminate to the breast give rise to cells which make up the bulk of the tumour mass but these are not the source of the distant metastases. ..
  18. McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. Gynecol Oncol. 2017;145:346-351 pubmed publisher
  19. Giannakeas V, Sopik V, Narod S. A model for ovarian cancer progression based on inherent resistance. Gynecol Oncol. 2016;142:484-9 pubmed publisher
    ..This observation has potential clinical implications about how to approach new therapies. ..
  20. Narod S. Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. Clin Genet. 2010;78:1-7 pubmed publisher
    ..These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2. ..
  21. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod S. Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016;143:433-438 pubmed publisher
    ..Studies of the mitogen-activated protein kinase (MAPK) inhibitor in low-grade serous ovarian cancer suggest that identifying MAPK mutations might eventually be useful in guiding treatment. ..
  22. Gronwald J, GLASS K, Rosen B, Karlan B, Tung N, Neuhausen S, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril. 2016;105:781-785 pubmed publisher
    ..66; 95% confidence interval 0.18-2.33) and the subsequent risk of ovarian cancer. Our findings suggest that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation. ..
  23. Sopik V, Nofech Mozes S, Sun P, Narod S. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat. 2016;155:175-85 pubmed publisher
    ..After local recurrence, the risk of death from breast cancer depends on the initial stage at diagnosis. ..
  24. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch H, Neuhausen S, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat. 2016;155:365-73 pubmed publisher
    ..These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer. ..
  25. Akbari M, Zhang S, Cragun D, Lee J, Coppola D, McLaughlin J, et al. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. Fam Cancer. 2017;16:351-355 pubmed publisher
    ..Patients with germline mutations often will have MSI-positive cancers and pre-screening of ovarian cancer specimens may be an efficient way of identifying patients with Lynch syndrome. ..
  26. Huzarski T, Byrski T, Gronwald J, Cybulski C, Oszurek O, Szwiec M, et al. The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2016;156:371-8 pubmed publisher
    ..44; 95 % CI 0.22-0.89; p = 0.02). Among women with breast cancer and a BRCA1 mutation, survival is greatly improved by oophorectomy due to the prevention of deaths from both breast and ovarian cancer. ..
  27. Young S, Pilarski R, Donenberg T, Shapiro C, Hammond L, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86 pubmed publisher
    ..Women with early-onset triple-negative breast cancer are candidates for genetic testing for BRCA1, even in the absence of a family history of breast or ovarian cancer. ..
  28. Narod S, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res Treat. 2018;168:513-521 pubmed publisher
    ..4%. The 10-year all-cause survival for women who had neither cisplatinum nor an oophorectomy was 65.4% (p < 0.01). Cisplatinum and oophorectomy are effective therapies for women with breast cancer and a BRCA1 mutation. ..
  29. Narod S, Neuhausen S, Vichodez G, Armel S, Lynch H, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008;99:371-4 pubmed publisher
    ..0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation. ..
  30. Sopik V, Iqbal J, Sun P, Narod S. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. Breast Cancer Res Treat. 2016;158:385-93 pubmed publisher
    ..This suggests that primary breast cancers and local invasive recurrences following DCIS are similar conditions and should be treated in the same way. ..
  31. Sopik V, Sun P, Narod S. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat. 2018;167:787-795 pubmed publisher
    ..00 (95% CI 1.76-2.26; p < 0.0001). In terms of prognosis, microinvasive cancer more closely resembles small invasive cancer 0.2-1.0 cm) than pure DCIS. For invasive cancers under 1.0 cm, size has little impact on mortality. ..
  32. Lubinski J, Marciniak W, Muszynska M, Huzarski T, Gronwald J, Cybulski C, et al. Serum selenium levels predict survival after breast cancer. Breast Cancer Res Treat. 2018;167:591-598 pubmed publisher
    ..Further studies are needed to confirm this association and to evaluate the impact of selenium supplementation on breast cancer survival among women with low post-diagnostic selenium levels. ..
  33. Giannakeas V, Narod S. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat. 2018;167:263-267 pubmed publisher
    ..8% at age 80, from 42.7 to 45.5%). Among BRCA mutation carriers, the mortality benefit of preventive mastectomy at age 25 is substantial, but the expected benefit declines rapidly with increasing age at surgery. ..
  34. Sopik V, Sun P, Narod S. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. Breast Cancer Res Treat. 2017;165:391-402 pubmed publisher
    ..72%; adjusted HR = 0.60; 95% CI 0.47-0.76; p < 0.0001). Positive ER-status is a favourable prognostic factor among women diagnosed with breast cancer at or above age 40, but not among women diagnosed before age 40. ..
  35. Finch A, Lubinski J, Møller P, Singer C, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547-53 pubmed publisher
  36. Narod S, Sopik V, Sun P. Which women decide to take tamoxifen?. Breast Cancer Res Treat. 2017;164:149-155 pubmed publisher
    ..These findings suggest that women consider the reduction in risk from local recurrence to be more important than the reduction in risk of death from breast cancer when they consider taking tamoxifen. ..
  37. Narod S, Moody J, Rosen B, Fan I, Risch A, Sun P, et al. Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet. 2013;83:232-7 pubmed publisher
    ..1% to 10.0%. The mortality advantage for tested women was due, in part, to a lower than expected mortality rate of tested women in the period following genetic testing. ..
  38. Kotsopoulos J, Lubinski J, Salmena L, Lynch H, Kim Sing C, Foulkes W, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14:R42 pubmed
    ..BRCA mutation carriers should be advised of the benefit of breastfeeding in terms of reducing breast cancer risk. ..
  39. Narod S. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat. 2011;128:581-3 pubmed publisher
    ..4% of women are expected to die of contralateral breast cancer within 5 years, but 6.8% are expected to die at 20 years from diagnosis. These unnecessary deaths can be prevented by bilateral mastectomy. ..
  40. Iqbal J, Ginsburg O, Giannakeas V, Rochon P, Semple J, Narod S. The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. Breast Cancer Res Treat. 2017;161:103-115 pubmed publisher
    ..52; P = .0006). Nodal micrometastasis is an independent risk factor for breast cancer mortality among women with early-stage breast cancer. Black women are more likely to die from breast cancer with micrometastases than white women. ..
  41. Narod S, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer. 2008;99:847-51 pubmed publisher
    ..Studies that examine how individual variants and their associated phenotypes affect prostate cancer presentation and progression are required. ..